Should Control Groups Receive the Current Standard of Care?

Can Researchers Withhold Existing Treatment to Test a New Intervention?

Imagine that researchers are evaluating a new treatment for a condition that already has an effective therapy. They could compare the experimental treatment against the existing therapy, but a placebo group might make it easier to determine whether the new treatment produces a measurable effect.

Would it be acceptable to give some participants placebo instead of the treatment they would ordinarily receive?

The problem becomes more complicated when clinical practice varies across hospitals, established treatments are unavailable in some settings, or the existing intervention provides only modest benefits. Researchers may also encounter circumstances in which usual care is not necessarily the best available care.

Deciding what the control group should receive is therefore both a methodological and an ethical judgment. It determines what the study can establish and what risks participants may face because of their assignment.

Established Effective Care Is Generally the Appropriate Starting Point

What Ethical Standards Actually Require of Clinical Trial Control Groups

What Does Standard of Care Mean in Research?

Standard of care generally refers to care recognized as professionally appropriate for a particular clinical condition and context. It may be informed by clinical guidelines, regulatory decisions, professional consensus, and evidence concerning the benefits and harms of available interventions.

However, the phrase does not always identify a single treatment. Several alternatives may be professionally acceptable, especially when patients differ in disease severity, contraindications, preferences, or treatment history.

In trial design, researchers must distinguish between what is routinely delivered and what is supported by the best available evidence. A practice can be common without being the most effective available option. Conversely, a proven treatment may be underused because of resource constraints or limited access.

These distinctions become particularly important when deciding whether the proposed control condition adequately protects participants.

Is Usual Care the Same as the Best Proven Intervention?

Not necessarily.

The Council for International Organizations of Medical Sciences (CIOMS) explains that an established effective intervention includes professionally recognized reasonable treatment options, not necessarily only the single best intervention.

For example, a hospital might routinely use an older treatment because a newer, more effective alternative is unavailable locally. Describing the older treatment as usual care does not automatically resolve whether it is the ethically appropriate comparator.

The relevant question is whether the proposed comparison satisfies the ethical obligations applicable to the participants and research setting.

What Does the Declaration of Helsinki Require?

The World Medical Association's Declaration of Helsinki is a major international ethical reference for medical research involving human participants. Its 2024 revision addresses comparator selection in Paragraph 33.

The declaration establishes comparison with the best proven intervention or interventions as the general principle for evaluating the benefits, risks, burdens, and effectiveness of a new intervention.

It recognizes two broad circumstances in which placebo or no intervention may be acceptable.

First, placebo or no intervention may be used when no proven intervention exists.

Second, a different comparator may be justified when compelling and scientifically sound methodological reasons require it, provided participants assigned to a less effective intervention, placebo, or no intervention will not face additional risks of serious or irreversible harm because they do not receive the best proven intervention.

The declaration explicitly cautions against abuse of this exception.

How Does CIOMS Guidance Address Control Groups?

CIOMS, working in collaboration with the World Health Organization, provides more detailed guidance through its International Ethical Guidelines for Health-related Research Involving Humans.

Guideline 5 addresses the choice of control in clinical trials and generally expects control participants to receive an established effective intervention.

It recognizes placebo use when no established effective intervention exists or when placebo is added to an established effective intervention.

When researchers propose withholding an established effective intervention, CIOMS requires compelling scientific reasons and a risk assessment showing that withholding or delaying the intervention would cause no more than a minor increase above minimal risk, with risks minimized through appropriate safeguards.

This is a more specifically articulated risk threshold than the serious-or-irreversible-harm formulation in the Declaration of Helsinki. Researchers should not assume that satisfying one ethical formulation automatically satisfies every applicable guideline or institutional requirement.

National regulations, research ethics committees, sponsors, and clinical specialties may impose additional obligations.

When Is a Placebo-Controlled Trial Ethically Acceptable?

A placebo-controlled trial may be ethically defensible when no established effective treatment exists and the proposed study has an acceptable risk-benefit profile.

Placebo can also be used in an add-on design in which both experimental and control participants continue receiving appropriate established treatment.

More difficult cases arise when an effective intervention exists but researchers argue that placebo is necessary to establish efficacy. The scientific justification must be compelling, and the additional risks of withholding treatment must satisfy applicable ethical requirements.

It is not sufficient to argue that placebo would produce a larger treatment difference, require fewer participants, or simplify analysis. Methodological convenience alone does not establish ethical permissibility.

Researchers should also consider whether an active-control trial, a shorter placebo exposure, rescue treatment, or another design could answer the research question with fewer risks.

The differences between placebo and other control conditions matter because these alternatives do not necessarily answer the same scientific question.

What Is an Add-On Trial, and Why Can It Be Ethically Useful?

An add-on trial evaluates a new intervention while maintaining an established background treatment for participants in both study groups.

For example, participants in one group might receive standard therapy plus the experimental treatment, while participants in the other receive standard therapy plus placebo.

This design estimates the incremental effect of adding the experimental intervention to the background treatment. It does not directly establish whether the experimental treatment could replace standard therapy.

Add-on designs may be useful when withdrawing existing treatment would be ethically problematic. However, interactions between treatments, adherence, adverse effects, and the appropriateness of combined treatment must still be evaluated.

What Happens When Standards of Care Differ Across Countries?

Multinational research can expose tensions between local clinical practice and internationally recognized evidence.

A treatment that is routinely available in a well-resourced setting may be inaccessible in another. Researchers cannot automatically justify a less effective control condition merely by arguing that participants would not otherwise receive the better treatment.

CIOMS guidance emphasizes the ethical responsibilities associated with established effective interventions, particularly in settings with limited resources.

Researchers should examine whether the proposed control condition exploits existing inequalities in access to treatment and whether alternative designs could answer the research question without withholding important benefits.

These questions are especially relevant when a trial is funded or organized by institutions outside the communities where participants are recruited.

Does Every Control Participant Have to Receive the Same Treatment?

No. An ethically appropriate standard-of-care comparator can involve several accepted treatments when clinical circumstances warrant different choices.

For example, participants may receive different approved therapies based on contraindications or clinical characteristics. A protocol can permit this flexibility while defining how treatment selection will occur.

The challenge is maintaining a scientifically interpretable comparison. Researchers should prespecify the permitted treatments, decision rules, documentation requirements, and relevant analytical considerations.

Uncontrolled variation can make it difficult to determine whether differences between groups arise from the experimental intervention or from inconsistencies in the comparator condition.

What If the Standard of Care Changes During the Trial?

Clinical evidence and treatment recommendations can change while a study is underway.

If a new treatment becomes established as more effective, researchers may need to reassess the ethical acceptability of the existing comparator and whether the protocol remains scientifically relevant.

Possible responses include protocol amendments, changes to background treatment, revised consent information, additional safety monitoring, or discontinuation of an ethically unacceptable comparison.

Such changes require careful coordination with research ethics committees, trial oversight bodies, and applicable regulatory authorities.

Researchers should also assess how the changes affect the interpretation of treatment effects and the original estimand.

Do the Same Rules Apply to Educational and Behavioral Research?

The underlying principles of scientific justification, proportional risk, fairness, and participant protection remain relevant, but clinical research guidance should not automatically be treated as binding regulation for every educational or behavioral study.

In educational research, the equivalent question might concern whether students in a control group should continue receiving their ordinary curriculum or established learning support.

For example, evaluating an experimental literacy program does not ordinarily justify depriving control students of compulsory instruction.

Researchers should distinguish routine educational provision from additional experimental services and evaluate whether the comparison creates unjustified disadvantages for participating students.

Applicable institutional review procedures, educational regulations, and safeguarding obligations should guide the decision.

Designing a Trial When Effective Treatment Already Exists

Suppose the team's actual question concerns whether the new intervention provides additional symptom improvement when combined with established therapy. An add-on design would directly address that question without requiring the control group to discontinue the established medication.

However, a positive result would establish the benefit of the combination relative to established therapy alone. It would not establish that the new intervention is an effective replacement for the established medication.

This distinction illustrates why ethical comparator selection and scientific interpretation must be considered together.

Misunderstandings About Standard-of-Care Requirements

How to Choose an Ethically Defensible Standard-of-Care Comparator

Before deciding what the control group should receive, identify the clinical decision your research is intended to inform and establish what effective interventions are already available.

The appropriate comparison may be an established active treatment, an add-on arrangement, or another carefully justified condition. Where withholding effective treatment creates unacceptable risk, methodological convenience should not determine the design.

It is also useful to consider whether alternative control arrangements can preserve participant welfare while still producing interpretable evidence.

Where the study uses routine care, investigate whether differences between comparison groups could distort the intended inference. Variation in access, treatment intensity, or background services may require additional design safeguards.

Finally, ensure the protocol states what happens if new evidence changes the accepted treatment standard during the study. Ethical responsibility continues throughout recruitment, intervention delivery, follow-up, and reporting.

Before Approving a Standard-of-Care Control, Verify These Points

Questions About Standard of Care and Trial Ethics

Protecting Participants Is Part of Designing a Valid Comparison

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.